₹ 3,925.29 Cr
1.95%
S&P BSE Healthcare TRI
INF109KC1GG4
5000.0
1000.0
500
Dharmesh Kakkad, Sharmila D'mello
Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
---|---|---|---|
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - IDCW Option | 55.68 | 15.35 | 26.79 |
S&P BSE Healthcare TRI | 50.08 | 13.58 | 22.23 |
Equity
Debt
Others
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Company | Holdings (%) |
---|---|
Sun Pharmaceutical Industries Ltd. | 14.88 |
Cipla Ltd. | 7.88 |
Dr. Reddy's Laboratories Ltd. | 7.55 |
Aurobindo Pharma Ltd. | 6.87 |
Lupin Ltd. | 6.17 |
Apollo Hospitals Enterprise Ltd. | 5.58 |
Divi's Laboratories Ltd. | 4.9 |
Gland Pharma Ltd. | 3.61 |
Mankind Pharma Ltd. | 2.97 |
Others | 2.86 |
Sector | Holdings (%) |
---|---|
Healthcare | 89.59 |
Chemicals | 4.61 |
Insurance | 3.79 |
Others | 2.01 |